This is a promotional meeting organised and funded by Roche Products Ltd.

A017029

For the past decade Roche has brought together the lung cancer community to share expertise, knowledge and solutions to the ever changing treatment landscape of lung cancer. This year, in addition to the 11th annual LCEF, we will also be taking the Lung Cancer Expert Forum digital. Please join us for the last in a series of three virtual meetings, in which we will explore various aspects of lung cancer treatment, sharing expertise from across the country.

A virtual meeting uses live, online interactive technology to allow delegates to access a meeting remotely. You can join the online presentations and ask text-based questions to be answered in the Q&A session at the end of each meeting.

This is an innovative way to learn about recent developments in treatments of lung cancer and to support best practice learning across the community.

Meetings

Completed: Tuesday 30 July 2019 | Session 1

Fast Progressing NSCLC patients and immunotherapy – what to do? – Dr Tim Benepal

In this session, Dr. Tim Benepal, Consultant Medical  Oncologist at St. George’s Hospital, will discuss the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy.

The two year stopping rule, how to handle this conversation with patients and your team – Dr Brian Clark

In this session Dr. Brian Clark, Consultant Clincal Oncologist at the Beatson West of Scotland Cancer Centre, discusses his experiences of effectively communicating with patients, families and the wider MDT. Focusing on delivering bad news, patient consent, and the 2 year immunotherapy stopping rule. He will address questions such as:

  • ‘What needs to be included in these conversations?’
  • ‘How can you make sure that patients understand the two year stopping rule?’
Completed: Wednesday 23 October 2019 | Session 2

18:30 – 18:35: Introduction

18:35 – 18:55: The science of immunotherapy combinations in 1L NSCLC – Professor Gary Middleton, Professor of Medical Oncology at the University of Birmingham.

In this session Professor Gary Middleton, Consultant Medical Oncologist at the Queen Elizabeth Hospital Birmingham will detail the proposed science behind the immunotherapy combinations currently available in the treatment of 1L NSCLC patients. Prof Middleton will specifically discuss and answer questions on Keynote-189 (pembrolizumab, cisplatin and pemetrexed) and IMpower150 (atezolizumab, bevacizumab, carboplatin and paclitaxel) combination therapies.

18:55 – 19:15: Patient Identification, clinical evidence and the practicalities of combination therapy for key patient subgroups in 1L metestatic non-squamous NSCLC – Dr Carles Escriu, Consultant Medical Oncologist at Clatterbridge Cancer Centre.

In this session Dr. Carles Escriu, Consultant Medical Oncologist at the Clatterbridge Cancer Centre will be explaining and sharing his experience on patient identification, clinical evidence and the practicalities of treating 1L metastatic non-squamous NSCLC patients using the IMpower150 regimen (atezolizumab, bevacizumab, carboplatin and paclitaxel).

19:15 – 19:30: Q&A Session

Completed: Wednesday 18th December 2019 | Session 3

Highlights from the Lung Cancer Expert Forum 2019 – Professor Marianne Nicolson, Aberdeen Royal Infirmary

In this session Professor Nicolson will reflect on some of the key highlights from this years annual Lung Cancer Expert Forum meeting, which will take place on 29th and 30th November in London. As the chair of the LCEF meeting, Professor Nicolson will provide key insights and her perspectives on the presentations, relating the content of the meeting to clinical practice in the UK.

Optimising the ALK+ NCSLC treatment pathway – Dr Brian Clark, Beatson West of Scotland Cancer Centre

In this session, Dr Brian Clark will present his perspectives on the optimal treatment pathway for ALK+ NSCLC patients based on clinical evidence and practice experience in managing these patients. Dr Clark will focus his discussion around the needs of an ALK+ patient, drawing on his own experience in managing these patients throughout their treatment journey.

Speakers

Here are some of the speakers who will be presenting the Virtual Lung Cancer Expert Forums:

Professor Marianne Nicolson

Consultant Medical Oncologist, Aberdeen Royal Infirmary

Read more

Professor Nicolson graduated with a BSc MBChB from
Edinburgh University medical school. After early postgraduate training in Edinburgh and Aberdeen, she did specialist training at the Royal Marsden Hospital and Institute of Cancer Research in London, gaining an MD and FRCP, before becoming a consultant medical oncologist at Aberdeen Royal Infirmary. Treatment and clinical research in lung cancer are Professor Nicolson’s main professional interests, and she has lectured and published extensively in lung cancer and other solid tumours. She is past chair of the UK NCRI lung cancer clinical studies group.

Dr Brian Clark

Consultant Clinical Oncologist, The Beatson West of Scotland Cancer Center

Read more

Dr Brian Clark is a Consultant Clinical Oncologist at The Beatson West of Scotland Cancer Center and BMI Ross Hall Hospital in Glasgow. After graduating from The University of Glasgow in 1999, he spent several years training in general (internal) medicine, accident and emergency, psychiatry and clinical haematology. In 2005 he started training in clinical oncology. In 2009, he was appointed as a Fellow of the Royal College of Radiologists and was awarded the Rohan Williams Medal for his performance in the FRCR examination. He has since been heavily involved in the FRCR examinations, has been a member of the FRCR Clinical Oncology Part 2A Question Writing Group since 2009 and has co-chaired the Group since 2015. He is also a member of the FRCR Fellowship Examination Board. Since January 2017, Dr Clark has been the Lung Cancer Lead Clinician for Ayrshire and Arran.

RXUKATEZ00577a(1)
November 2019

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.

This is a promotional meeting organised and funded by Roche Products Ltd.

The link you have selected will take you away from this site to one that is not owned or controlled by Roche Products Ltd. Roche Products Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.